results reported in the literature with 16 Cr(VI) compounds, Estimates of the overall reducing capacity of hexavalent up to 1990, were positive in short-term tests evaluating genetic chromium(VI) in some human body compartments were and related effects (1, 2) . Cr(VI) is carcinogenic to humans made by relating the specific reducing activity of body (3), but epidemiological studies provide evidence that its fluids, cell populations or organs to their average volume, carcinogenicity is strictly site-specific. In fact, according to number, or weight. Although these data do not have the International Agency for Research on Cancer (IARC), absolute precision or universal applicability, they provide there is sufficient evidence for carcinogenicity in the lung and a rationale for predicting and interpreting the health effects in the sinonasal cavity, while for other sites 'no consistent of chromium(VI). The available evidence strongly indicates pattern of cancer risk has been shown among workers exposed that chromium(VI) reduction in body fluids and long-lived to chromium compounds' (3). Review of the epidemiologic non-target cells is expected to greatly attenuate its potential literature and other evidence concerning Cr(VI) carcinogenicity toxicity and genotoxicity, to imprint a threshold character that has been published since the IARC review does not alter to the carcinogenesis process, and to restrict the possible this conclusion. As cited in the IARC monograph (3), the targets of its activity. For example, the chromium(VI) epidemiologic evidence for increased risk of cancers of the sequestering capacity of whole blood (187-234 mg per lung and sinonasal cavity is limited to conditions of high individual) and the reducing capacity of red blood cells (at exposure, 'as encountered in the chromate production, chromate least 93-128 mg) explain why this metal is not a systemic pigment production and chromium plating industries' (3), toxicant, except at very high doses, and also explain its which in the past decades involved mixed exposures to various lack of carcinogenicity at a distance from the portal of Cr(VI) compounds and possibly to other metals as well as entry into the organism. Reduction by fluids in the digestive organic substances. tract, e.g. by saliva (0.7-2.1 mg/day) and gastric juice (at Experimental studies in rodents were expected to contribute least 84-88 mg/day), and sequestration by intestinal bacto the identification of carcinogenic Cr(VI) compounds. Howteria (11-24 mg eliminated daily with feces) account for ever, by analysing the data reviewed by IARC (3), not only the poor intestinal absorption of chromium(VI). The chronone of the six studies performed with metallic chromium or mium(VI) escaping reduction in the digestive tract will be of the 21 studies performed with Cr(III) compounds was detoxified in the blood of the portal vein system and then positive, but even less than half of the 65 studies performed in the liver, having an overall reducing capacity of 3300 mg.
with Cr(VI) compounds (41.5%) was positive. Moreover, the These processes give reasons for the poor oral toxicity majority of positive results were generated in studies involving of chromium(VI) and its lack of carcinogenicity when certain exposure routes (subcutaneous, intramuscular, intraperiintroduced by the oral route or swallowed following reflux toneal, intrapleural, intrabronchial) which by-pass important from the respiratory tract. In terminal airways chrodetoxification barriers and do not reproduce any human expomium(VI) is reduced in the epithelial lining fluid (0.9-sure (2). All patterns of experimental carcinogenicity with 1.8 mg) and in pulmonary alveolar macrophages (136 mg).
Cr(VI) compounds point to the existence of threshold mechanThe peripheral lung parenchyma has an overall reducing isms, as indicated by the high frequency (58.5%) of negative capacity of 260 mg chromium(VI), with a slightly higher results, attributable to a complete Cr(VI) detoxification in specific activity as compared to the bronchial tree. Theretreated animals, or induction of cancer only under particular fore, even in the respiratory tract, which is the only conditions, e.g., (a) at extremely high doses, saturating detoxiconsistent target of chromium(VI) carcinogenicity in fication mechanisms, (b) at implant sites only, and never at a humans (lung and sinonasal cavities), there are barriers distance from the portal of entry into the organism, (c) in hampering its carcinogenicity. These hurdles could be only certain targets only, selected by the lack of detoxification overwhelmed under conditions of massive exposure by mechanisms, or (d) when given in a single massive dose, and inhalation, as it occurred in certain work environments not in the same cumulative amount fractionated into smaller doses which can be more easily detoxified (2,4). (8) . Since the daily secretion of saliva in humans is in the 500-1500 ml range of detoxification mechanisms of Cr(VI), mainly based on reduction to Cr(III), which is not carcinogenic and does not (14) , this mechanism will reduce daily 0.7-2.1 mg Cr(VI). bear any toxicological relevance (1) (2) (3) 6, 7) .
Gastric juice Based on these studies and on new experiments designed
The Cr(VI)-reducing activity of gastric juice samples from ad hoc, we made quantitative estimates of the overall Cr(VI)-four fasting individuals was found in an earlier study to be reducing or sequestering capacity of some human body com-9.2 Ϯ 0.4 µg/ml fluid (8) . Later on, a detailed study regarding partments by taking into account the specific Cr(VI) reducing the reducing ability in the gastric environment was performed activity of body fluids, cells or organs, and their average in 17 individuals, both males and females, in whom samples volume, number or weight in humans. We use the general of gastric juice were aspirated at hourly intervals by means of term sequestration when intact cells were tested and the term a nasogastric tube (9) . The baseline of Cr(VI)-reducing activity reduction when cell homogenates or their subfractions were during interdigestive periods (mainly during the night) was tested in the presence of an exogenous NADPH-generating 8.3 Ϯ 4.7 µg/ml, i.e. very similar to the one detected in the system. previous study. After each one of the three daily meals there were periods of 3-4 h during which peaks of 50-60 µg/ml Materials and methods were recorded, averaging 31.4 Ϯ 6.7 µg Cr(VI) reduced per
The Cr(VI) reducing capacity was estimated by multiplying the specific ml gastric juice during these periods. It is known that in a reducing activity of a given organ, cell population, or fluid, expressed as µg fasting individual the gastric secretion accounts for 1000-Cr(VI) reduced per unit of weight, volume or number, by the average content of the same organ, cell population or fluid in the human body. The Cr(VI) 1500 ml (15) , and in the 4-h period after each meal an average reducing activity was inferred from our previous studies in the case of saliva amount of~800 ml is additionally secreted (16) . Therefore, (8) , gastric juice (8, 9) , epithelial lining fluid (ELF) (10) , pulmonary alveolar the overall Cr(VI) reduction by gastric juice may be estimated macrophages (PAM) (10), peripheral lung parenchyma (11) and bronchial to be at least 84-88 mg per day (8.3 µg/mlϫ1000-1500 ml tree (12).
ϩ 31.4 µg/mlϫ800 mlϫ3 meals).
New experiments were carried out for assessing the sequestering activity of human intestinal bacteria or of whole blood, and the reducing ability of Cr(VI) reduction by gastric juice is due both to thermostable red blood cell (RBC) lysates or of liver homogenates. We refer to the previously components of this fluid and to food components (9) . Since mentioned papers for technical details. Briefly, 25% liver homogenates were gastric juice samples were centrifuged before being challenged colon. The average fecal mass is 124 Ϯ 40 g/day, and its dry lysates. After 60 min of gentle mixing at 37°C, the mixtures were evaluated for the amount of residual Cr(VI), both by using the colorimetric method with mass is 21 Ϯ 5 g/day, 14-30% of which is represented by s-diphenylcarbazide (10) and/or by assessing mutagenicity in strains TA100 bacteria (14) . Accordingly, 2.9-6.3 g of bacteria are eliminated and TA102 of Salmonella typhimurium (13) . Due to the turbidity of mixtures, daily with feces. Taking into account that 10 12 bacteria weigh only the mutagenicity test system, used as a 'biological spectrophotometer',~1 g and are capable of sequestering 3.8 mg Cr(VI), it can be could be applied in the case of liver homogenates and RBC lysates. The calculated that 11-24 mg Cr(VI) can be eliminated daily with amounts of residual Cr(VI), and consequently the amounts of reduced or sequestered Cr(VI), were calculated from the regression lines relating the fecal bacteria. Unfractionated homogenates of liver, obtained at surgery from Results three males, reduced 2.2 Ϯ 0.9 mg Cr(VI)/g wet tissue, after contact for 60 min at 37°C in the presence of S9 mix, as Table I reports the volume, weight or number of selected evaluated by assessing the decrease of sodium dichromate fluids, organs or cell populations in the human body, along mutagenicity in strains TA100 and TA102 of S.typhimurium. with their ability to reduce or sequester Cr(VI). Accordingly, Since the average weight of the human liver is 1500 g, not the overall Cr(VI) reducing or sequestering capacity of fluids, taking into account 400-800 g of blood circulating in this organs or cells was calculated either on a daily basis or in organ (18), we estimated an overall reducing capacity of terms of saturating amounts of Cr(VI). The results of these 3300 mg Cr(VI). estimates are further summarized in Figure 1 .
Blood Saliva Samples of saliva from five subjects (three males and two
We evaluated Cr(VI) sequestration by whole blood as well as its reduction by the soluble fraction of red blood cell (RBC) females), incubated with Cr(VI) for 5 min at 37°C, reduced (15) periods ϩ800 ml/meal (16) 31.4 Ϯ 6.7 µg/ml (9) ϩ25.1 mg/meal 3400-3900 ml/day (3 meals) Ͼ84-88 mg/day (3 meals)
Intestinal bacteria 2.9-6.3 g eliminated daily with feces 3.8 Ϯ 1.7 µg/10 9 bacteria a 11-24 mg eliminated daily with feces (14) Liver 1500 g (18) 2.2 Ϯ 0.9 mg/g liver homogenate a 3300 mg
Whole blood 4490 ml (males) (14) 52.1 Ϯ 5.9 µg/ml 234 mg (males) 3600 ml (females) (14) intact blood a 187 mg (females)
Red blood cells (RBC) 2030 ml (males) (14) 63.4 Ϯ 8.1 µg/ml 128 mg (males) 1470 ml (females) (14) RBC Peripheral lung parenchyma 1300 g (18) 0.2 Ϯ 0.07 mg/g 260 mg lung S12 fraction (11) a This study.
The RBC lysate soluble fractions from the same subjects were assayed in the mutagenicity test system. In the presence of S9 mix, 1 ml portions of the RBC lysates reduced 63.4 Ϯ 8.1 µg Cr(VI) within 60 min at 37°C. According to this experimental approach and to the known volumes of RBC in males and females (see Table I ), we calculated an overall reduction of 128 and 93 mg Cr(VI), respectively. This is an underestimate of the overall reducing capacity of RBC, since the RBC stromal fraction was removed by centrifugation. These results are comparable to those obtained in a previous study (19), in which an appreciable decrease of Cr(VI) (as chromic acid) mutagenicity by RBC lysates was even observed in the absence of an exogenous NADPH-generating system (i.e. S-9 mix).
Epithelial lining fluid (ELF)
The ELF includes the surfactant and those bronchial and bronchiolar secretions which can be recovered by bronchoalveolar lavage. Amounts of 23.7 Ϯ 15.9 µg Cr(VI) (mean Ϯ SD in 15 individuals, both males and females) were reduced by each ml of ELF after contact for 4 h (10). Since the total volume of ELF has been reported to be between 37.5 and 75 ml (20), its overall reducing capacity can be estimated to be 0.9-1.8 mg Cr(VI) per individual. 
Pulmonary alveolar macrophages (PAM)
The total number of these sweeping cells in the normal human lung at any given time is estimated to be 23 billion, with~50-lysates from three subjects, two males and one female. After contact of sodium dichromate [100 µg Cr(VI)] with 1 ml 100 PAM per alveolus (21). We evaluated Cr(VI) reduction by PAM S9 fractions after 30 min at 37°C. Expressed as µg heparinized venous blood for 60 min at 37°C, an average of 47.9 µg was recovered from plasma, thus indicating that Cr(VI) reduced per 10 6 cells, the results were as follows: 2.4 Ϯ 1.1 (mean Ϯ SD in four non-smokers), 3.6 Ϯ 0.7 (eight 52.1 Ϯ 5.9 µg had been sequestered by blood cells or reduced by plasma itself. Similar data were obtained by measuring exsmokers), 5.8 Ϯ 1.2 (6 current smokers) and 6.3 Ϯ 1.1 (five subjects smoking during the last 2 h before bronchoalveolar residual Cr(VI) either by colorimetric analysis or in the mutagenicity test system with strains TA100 and TA102 of lavage). The specific reducing activity of PAM in smokers was significantly higher (P Ͻ 0.01) than that in non-smokers S.typhimurium. Taking into account the average volumes of blood in males and females (see Table I ), we calculated an and exsmokers. The average Cr(VI) reduction capacity was 4.4 Ϯ 3.9 µg/10 6 PAM in 23 subjects of both sexes (10) . In overall sequestration of 234 and 187 mg Cr(VI), respectively. the same study we established that the reducing activity of lifespan of human RBC is 107Ϯ12 days (14) , every day a population corresponding to 1/107th of the total RBC volume, unfractionated PAM homogenates was 1.33 times higher than that of the corresponding S9 fractions (10) . Therefore, we i.e., 19 ml in males and 14 ml in females, will be renewed. Moreover, even in organs characterized by a poor turnover of introduced this correction factor for estimating the overall Cr(VI) reducing capacity by PAM (136 mg per individual) . cells, such as the liver, there is a continuous synthesis of glutathione (GSH) and other reducing molecules which, besides Peripheral lung parenchyma exerting protective effects locally, are exported to other organs. Cr(VI) reduction by S12 fractions of peripheral lung parenAs extensively discussed in previous articles (1,2,4,6,8,23-chyma was assessed in tissue samples taken at surgery from 25), Cr(VI) reduction in biological fluids (e.g. saliva, gastric 71 male subjects. After incubation with sodium dichromate juice and ELF) and long-lived non-target cells (e.g. RBC and for 60 min at 37°C in the presence of S9 mix, the observed PAM) is expected to greatly attenuate Cr(VI) toxicity, to decrease in mutagenicity in strain TA100 of S.typhimurium imprint a threshold character to the carcinogenesis process and corresponded to reduction of 0.24 Ϯ 0.07 mg Cr(VI) per to restrict the targets of its potential activity. In fact, Cr(III), g wet tissue (11) . Interestingly, the reducing activity was the stable reduced form of chromium, is not mutagenic in significantly higher (P Ͻ 0.05) for tissues obtained from 45 bacteria (1-3) and does not bear toxicological relevance in the smokers (0.25 Ϯ 0.07 mg/g), as compared to 26 non-smokers extracellular environment, due to its poor ability to cross cell (0.22 Ϯ 0.06 mg/g), and the 19 individuals who smoked during membranes (4). Provided Cr(VI) may overwhelm a series of the last 24 h preceding surgical operation exhibited even hurdles and penetrate into cells, it will be reduced to Cr(V), greater reduction capacity (0.27 Ϯ 0.06 mg/g) (11). Again, a Cr(IV) and Cr(III) by a complex network of mechanisms, both 1.33 correction factor extrapolating from S12 fractions to enzymatic and nonenzymatic, which may also lead to the unfractionated homogenates was introduced for estimating the generation of reactive oxygen species (4, 26) . Depending on overall Cr(VI) reducing capacity of the lungs (260 mg per proximity to DNA, these processes may result in DNA damage individual).
by these reactive species, or in trapping by cell nucleophiles Bronchial tree and consequently in detoxification (4) . It is meaningful, in this respect, that tissues which are typical targets for Cr(VI) Peripheral lung parenchyma and bronchial tree S12 fractions carcinogenicity in rodent assays, such as the rat skeletal muscle from 18 of the above mentioned subjects were compared for after local implantation (3), have a negligible activity in their ability to decrease the mutagenicity of sodium dichromate.
decreasing Cr(VI) mutagenicity (19). Thus, tissue-specific There was a statistically significant correlation between the susceptibility to Cr(VI) tumorigenicity correlates with intrinsictwo preparations in decreasing Cr(VI) mutagenicity, peripheral ally poor capacity for intracellular Cr(VI) reduction. lung parenchyma being slightly yet significantly more efficient
The investigated mechanisms and quantitative estimates on in accomplishing this process (12) . These findings refer to Cr(VI) reduction may predict and explain the fate of this metal whole bronchial tissue preparations, since it was not possible in the human body. The massive reducing and sequestering to dissect sufficient amounts of bronchial epithelium for capacity of the blood explains why Cr(VI) exerts its toxicoassessing the endpoints under study. The lack of information logical consequences only at the portal of entry into the on the weight of bronchial tree does not allow us to estimate organism, while it is not a systemic toxicant or carcinogen. In its overall reducing capacity per individual.
fact, Cr(VI) carcinogenicity in humans is restricted to the sinonasal cavity and the lung, whereas excess risks reported Discussion for cancer at other sites were inconsistent and not convincingly associated with Cr(VI) exposure (3). In only one out of the The results of the present study provide for the first time estimates aimed at quantitating the ability of organs, cell 65 carcinogenicity studies in rodents reported by IARC (1990), Cr(VI) was found to be carcinogenic at a distance from the populations and fluids in the human body to sequester or reduce Cr(VI). It is clear that the reported data do not have administration site, specifically in rats receiving intramuscular injections of lead chromate, which developed renal carcinomas absolute precision or universal applicability for several reasons. For example, all estimates were inferred from ex vivo experi-(27). However, this effect should be ascribed to lead, which typically produces kidney tumors in rodents (28), rather than ments which, depending on the specific test design, could overstate or underestimate the reduction or sequestration proto chromate. In the present study,~200 mg Cr(VI) were estimated to be cess in vivo. Inter-individual differences in these parameters should also be taken into account to infer the reduction capacity sequestered by whole human blood. About half of this figure was found to be reduced in the presence of the soluble fraction of various compartments in a specific person. Moreover, the overall reducing or sequestering capacity was estimated by of RBC lysates. This difference is likely due to the fact that preparations of RBC lysates involves elimination of their hypothetically assuming a uniform distribution of Cr(VI) in the body compartment under evaluation. stromal fraction by centrifugation and loss of biochemical activities, which are partially restored by adding an exogenous Some data, e.g. Cr(VI) reduction in saliva and gastric juice, or its sequestration by bacteria, could be estimated on a daily NADPH-generating system. In addition, blood plasma has been reported to reduce up to 2 µg Cr(VI) per ml blood basis. All remaining data refer to the overall capacity of fluids, organs or cells. Nevertheless, the reported estimates do not (29, 30) . Since the mean plasma volume is 2640 ml in adult males and 2130 ml in adult females (14) , the overall Cr(VI) reflect rigid saturation levels, unless following massive acute exposure, since there is a continuous production of body fluids reducing capacity of blood plasma can be estimated to be 4.9 and 4.2 mg, respectively. A recent investigation (31) examined and turnover of certain cell populations. For instance, 1-5 million PAM in the human lungs are removed every hour the rate and capacity of Cr(VI) reduction in human blood in vitro and reported findings that agree well with data via the mucociliatory escalator to be either expectorated or swallowed (22). Taking into account that the mean (Ϯ SD) generated in the present study. The major detoxification occurs in RBCs, where since many years it is known that Cr(VI) is years to Cr(VI) in drinking water derived from an aquifer contaminated by effluent from a chromate alloy facility (49) . selectively accumulated (32) and reduced to Cr(III) (especially A series of recent studies indicate that the relatively high by GSH) and bound to low-molecular weight components and reducing capacities related to oral ingestion are effective in chiefly to hemoglobin (33-38). These mechanisms also help (a) dramatically attenuating chromium absorption into the to explain why all chromium detectable in the urine of exposed blood; (b) preventing any measurable entry of chromium in individuals is Cr (III) (3,39) . the hexavalent form into the blood, (c) preventing any increase Formidable barriers hamper the potential toxicity of Cr(VI) in a putative marker for blood uptake of Cr(VI) (DNA-protein when introduced by the oral route or swallowed either following cross-links in peripheral lymphocytes) and (d) controlling the reflux from the respiratory tract or following impact onto the absorption, distribution and excretion of Cr(III) complexes proximal aerodigestive tract of inhaled Cr(VI) associated with that are formed following ingestion of Cr(VI) at plausible large-size particles. After reduction in the oral cavity by saliva, concentrations in drinking water (39, (50) (51) (52) (53) . Each of these which would be sufficient to detoxify Cr(VI) contained in studies monitored total chromium concentrations in RBCs, several liters of drinking water at the standards recommended plasma and urine over time to assess bioavailability and in several countries (0.05-0.1 mg/l), an efficient reduction potential Cr(VI) uptake into the blood, using RBC chromium occurs in the stomach, accounting for at least 84-88 mg per levels as a primary biomarker for such uptake. Human volunday. A further hurdle is represented by intestinal bacteria teers in these studies ingested water containing Cr(VI) or which, as estimated just from the aliquot of bacteria eliminated Cr(III) at concentrations up to 10 mg/l for as long as 17 with feces, will sequester daily 11-24 mg Cr(VI). Intestinal consecutive days. In sum, these studies suggest that ingestion bacteria are known to contain high amounts of GSH (40), of Cr(VI) in drinking water at plausible chronic exposure which efficiently reduces Cr(VI) (4) . A Cr(VI) reducing role concentrations (i.e. at or below 0.5 to 2 mg/l, when yellow has been also ascribed to enterobacterial enzymes, such as discoloration becomes apparent) results in minimal uptake of nitroreductases (4) . Since bacterial GSH is released extracelluchromium into the blood. Further, the RBC and plasma larly (40) , an additional Cr(VI) reducing activity is also likely chromium concentration patterns following exposures to Cr(VI) to occur in the extracellular environment of the intestinal in drinking water at up to 10 mg/l suggest that Ͼ99.7% of the lumen. All these mechanisms explain the poor absorption of ingested dose is reduced in the gastrointestinal tract prior to Cr(VI) in the intestine (41, 42) . In case some amount of Cr(VI) absorption into the blood. Thus, the pharmacokinetics of may escape detoxification, it will penetrate into the blood of the Cr(VI) at plausible chronic doses in drinking water mimics portal vein and, in case even this barrier may be overwhelmed, it that of organic complex forms of Cr(III) (e.g. vitamin forms will reach the liver, which is capable of reducing grams of such as the tripicolinate or the glucose tolerance factor), likely Cr(VI) daily. As a consequence, Cr(VI) is poorly toxic by the due to formation of such complexes upon contact with organic oral route. In fact, only few lethal effects were observed in reducing agents present in the gastric contents, tissues and episodes of accidental ingestion of high doses of Cr(VI) by blood. humans (6) . For instance, following acute ingestion in the In addition to well-known non-specific defense mechanisms range between 8 and 20 g of Cr(VI) compounds, eight subjects of the respiratory tract (22), reduction in the ELF and in PAM survived and three subjects died (6) . The LD 50 in rodents is supports the view that Cr(VI) encounters efficient detoxification Ͼ50 mg Cr(VI)/kg body weight (43) .
barriers following inhalation. This is consistent with the The defence mechanisms are even more effective after premise that even for the primary target organ of Cr(VI) in repeated ingestion of smaller Cr(VI) doses, which can be humans there is likely a threshold for adverse effects including readily detoxified and, therefore, do not result in cumulative cancer, that is related to the reduction capacities of intrinsic phenomena, including mutagenicity and carcinogenicity. For defense mechanisms (54) . The ELF layer has an average instance, a family accidentally exposed to Cr(VI) at 1 mg/l in thickness in the 0.54-1.07 µm range over the 70 m 2 of alveolar well water for three years was reported to have no adverse surface of each individual (20). This fluid is particularly rich effects (44) . Dogs fed 11.2 mg/l Cr(VI) for 4 years (45), and in antioxidants, such as GSH, vitamin C (ascorbic acid), rats fed 25 mg/l for 1 year (46) or 134 mg/l for 6 months (47) vitamin E (tocopherol), superoxide dismutase, catalase, albuexhibited no adverse effects from these chronic exposures.
min, ceruloplasmin, transferrin, lactoferrin and other proteins Similarly, a recently published investigation showed a lack (55) . In rats the Cr(VI) reducing activity of ELF has been of genotoxic effects after oral administration of potassium mainly ascribed to ascorbic acid (56) , but in humans GSH dichromate at up to 20 mg of Cr(VI) per liter of drinking levels are particularly high in ELF (57) . Even more important water, or administration of a similar amount by gavage, in is phagocytosis and reduction of Cr(VI) by PAM, that we either the mouse bone marrow micronucleus assay or the rat estimated to reduce 136 mg/day/individual. The reducing in vivo-in vitro rat hepatocyte DNA repair assay (48) . In activity of rat PAM was of the same order of magnitude as addition, a three-generation study of drinking water exposure that of human PAM from non-smokers, i.e., around 2 µg to potassium chromate in rats failed to demonstrate treatmentCr(VI)/10 6 cells (58). Peripheral lung parenchyma showed an related increases in carcinogenicity following lifetime expoappreciable Cr(VI) reducing capacity (260 mg/individual), sures (47) . This observation is in agreement with the fact that although it appears to be 12.7 times lower than that of the no consistent pattern of excess risk for cancer of the digestive liver, which is also known to be more efficient than the lung tract emerged from a large number of epidemiologic studies in repairing DNA damage (59) . It is also noteworthy that of Cr(VI) workers (3), despite the fact that massive exposures Cr(VI) is capable of inducing its own pulmonary metabolism by inhalation presumably involved swallowing of Cr(VI). (60) . On the whole, there is evidence that the human respiratory Furthermore, no exposure-related increase in stomach cancers tract has considerable defence mechanisms towards Cr(VI), or overall cancer mortality was reported in a recent evaluation although they are not as outstanding as those of the digestive tract. These processes unequivocally support the existence of of a residential population in China exposed for up to 6 
